1. Treating mRCC After Initial Antiangiogenic Therapy:

3. Introduction

4. Choice of Systemic Therapy for RCC

5. Second-Line Therapy for Advanced RCC

6. PFS by Subgroup: AXIS Study

7. VEGF-TKI vs mTOR Inhibitor: Historical Perspective

8. Treatments in Advanced RCC: Different Therapeutic Options

9. Treatment Approach to Non-Clear Cell RCC

10. Treatment Options for Non-Clear Cell RCC

11. Study of a Dual MET/VEGFR2 Inhibitor in Patients With Papillary RCC

12. Second-Line Treatment of Clear Cell RCC: A Multifaceted Approach

13. Second-Line Treatment of Clear Cell RCC: A Multifaceted Approach (cont)

14. Second-Line Treatment of Clear Cell RCC: A Multifaceted Approach (cont)

15. EAU Guidelines for Clear Cell Renal Cancers Resistant to VEGFR-Targeted Therapy

16. Clinical Trials With Nivolumab in Advanced RCC

17. Predictive Biomarkers in PD-1/PD-L1 Checkpoint Blockade Immunotherapy

18. QoL in Patients With Advanced RCC: Nivolumab vs Everolimus

19. Mechanism of Action of Cabozantinib

20. Optimization of Targeted Therapy in Advanced RCC

21. Cabozantinib vs Everolimus in Advanced RCC: Results of METEOR Trial*

22. Cabozantinib vs Everolimus in Advanced RCC: Results of METEOR Trial (cont)

23. Rationale for Combination Therapy in Advanced RCC Treatment

24. Lenvatinib Plus Everolimus in Patients With mRCC

25. Lenvatinib Plus Everolimus in Patients With mRCC: OS (Post-Hoc Updated Analysis)

26. Cabozantinib Dosing

27. Most Common Grade 3-4 Treatment-Emergent AEs Regardless of Causality Reported in the METEOR Trial*

28. Cabozantinib: Dose Reductions vs Dose Interruptions

29. Grade 3-4 Treatment-Related AEs Reported in the CheckMate 025 Study*

30. Choice of Therapy for VEGF-Resistant Disease

31. Choice of Therapy for VEGF-Resistant Disease (cont)

32. Summary and Conclusions